JewishStatusOpen the app

The Lakewood Scoop · Jul 21, 2026

The Lakewood Scoop — photo status

New Hope for High Cholesterol Patients: First-of-its-Kind Pill Gets FDA Approval As millions of Americans struggle to control their high cholesterol with diet, exercise, and statin therapy, the U.S. Food and Drug Administration (FDA) has approved a groundbreaking new treatment: Lipfendra (enlicitide). This is the first and only oral PCSK9 inhibitor, offering a convenient once-daily pill for a powerful class of cholesterol-lowering drugs that, until now, was only available as an injection. This new development is a beacon of hope for patients who have had difficulty managing their cholesterol with statins alone or who are hesitant to use injectable therapies. “The approval of an oral PCSK9 inhibitor is a monumental step forward in our fight against cardiovascular disease,” says Dr. Nathaniel Lebowitz, a board-certified cardiologist and cholesterol specialist with over 20 years of experience in preventive cardiology. Dr. Lebowitz has dedicated his career to studying and treating cholesterol disorders, including challenging cases of genetic high cholesterol. “For decades we’ve relied on a limited number of tools to help our patients manage their cholesterol. This is a game-changer for preventive cardiology.” READ MORE ⤵️ Click here to join the official TLS Community:

*New Hope for High Cholesterol Patients: First-of-its-Kind Pill Gets FDA Approval* As millions of Americans struggle to control their high cholesterol with diet, exercise, and statin therapy, the U.S. Food and Drug Administration (FDA) has approved a groundbreaking new treatment: Lipfendra (enlicitide). This is the first and only oral PCSK9 inhibitor, offering a convenient once-daily pill for a powerful class of cholesterol-lowering drugs that, until now, was only available as an injection. This new development is a beacon of hope for patients who have had difficulty managing their cholesterol with statins alone or who are hesitant to use injectable therapies. “The approval of an oral PCSK9 inhibitor is a monumental step forward in our fight against cardiovascular disease,” says Dr. Nathaniel Lebowitz, a board-certified cardiologist and cholesterol specialist with over 20 years of experience in preventive cardiology. Dr. Lebowitz has dedicated his career to studying and treating cholesterol disorders, including challenging cases of genetic high cholesterol. “For decades we’ve relied on a limited number of tools to help our patients manage their cholesterol. This is a game-changer for preventive cardiology.” READ MORE ⤵️ https://thelakewoodscoop.com/news/new-hope-for-high-cholesterol-patients-first-of-its-kind-pill-gets-fda-approval/ ~~~ Click here to join the official TLS Community: https://chat.whatsapp.com/GGwlPaiG0d49MJTRLfHVPN ~~~

Watch in the app All of The Lakewood Scoop's statuses

More from The Lakewood Scoop